financial highlights in april 2017 , we sold 3,732,356 shares of our common stock and warrants to purchase 1,866,178 shares of common stock with an exercise price of $ 4.10 per share , or the april 2017 warrants for aggregate net proceeds of $ 10.9 million . in august 2017 , we sold an aggregate of 34.0 million shares of our common stock for net proceeds of $ 33.7 million . in connection with this offering , we repurchased the april 2017 warrants . in august 2018 , we announced additional purchase orders by ford motor company for the eksovest as part of an expanded initiative to help reduce the physical toll of repeated overhead tasks among ford assembly line workers , in which eksovest was supplied to 15 ford assembly plants in seven countries . in august 2018 , we entered into a controlled equity offering sm sales agreement , or the atm agreement , under which we may issue and sell shares of our common stock , having an aggregate offering price of up to $ 25.0 million . in the year ended december 31 , 2018 , we sold 2.0 million shares of our common stock under the atm agreement at an average price of $ 2.39 per share , for aggregate proceeds of $ 4.4 million , net of commission and issuance costs , to us . in december 2018 , we secured purchase orders for the eksovest from two global aerospace manufacturers to create and expand pilot programs , respectively . the assistive devices will be piloted by workers on the assembly production lines of commercial and defense airplanes to enhance safety , reduce fatigue and risk of injury . in january 2019 , we entered into the china jv to develop and serve the exoskeleton market in china and other asian markets and to create a global exoskeleton manufacturing center . in connection with the china jv , one of the joint venture partner affiliates agreed to purchase an aggregate of 3,067,485 shares of our common stock at a price per share equal to $ 1.63 , for aggregate proceeds to us of $ 5.0 million , which we received in february 2019. in addition , within thirty ( 30 ) business days of the china jv delivering its first batch of finished eksogt products to a buyer , the china jv or the joint venture partner are to invest a further $ 5.0 million in our company in accordance with the terms of the jv agreement . business we design , develop and sell exoskeleton technology that currently has applications in healthcare and industrial markets . our wearable exoskeletons are worn over clothing and are mechanically controlled by a trained operator to augment human strength , endurance and mobility . our exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities . we have sold and rented devices that ( a ) enable individuals with neurological conditions affecting gait ( e.g . , sci or stroke ) to rehabilitate and to walk again ; and ( b ) allow industrial workers to perform heavy duty or repetitive work for extended periods . in the u.s. there are about 5.9 million stroke and sci rehabilitation sessions conducted on about 680,000 stroke and sci patients at 16,900 facilities , according to lexisnexis risk solutions medical claims data . the first step to achieving our goal is for us to focus on selling and renting our medical exoskeletons to rehabilitation centers and hospitals in the united states and europe . ekso bionics began that effort with the february 2012 sale of ekso , an exoskeleton for 37 sci rehabilitation . we expanded that effort with the launch of our variableassist software . variableassist software enables users with any amount of lower extremity strength to contribute their own power for either leg to achieve self-initiated walking . next , we introduced ekso gt and smartassist which builds on the experience of ekso and variableassist , allowing us to expand our sales and marketing efforts beyond sci-focused centers to centers supporting stroke and related neurological patients . we also continue to offer rental options for ekso gt to our customers as part of our sales strategy to familiarize customers with the device and demonstrate the value-add to their business , as well as increase adoption . all rentals or sales also include customer training , comprised of both on-line and in-person training of our customers ' physical therapists , to get our customers comfortable using our product and understanding its functionality . we have continued to progress toward our goal with the roll out of our latest breakthrough innovation , smartassist . smartassist can aid in promoting early mobility by training patients ( pregait ) to walk in an exoskeleton , which should expand access to care to more patients . smartassist also includes next generation variableassist technology that provides more freedom for healthcare providers to allow patients to power themselves ( freegait ) in the most appropriate ways possible . additionally , we have strengthened our competitive position as an exoskeleton manufacturer in medical rehabilitation by introducing a cloud-based software platform named eksopulse analytics , which gathers and transmits statistics and device information in real time during ekso gt walking sessions . this feature enables more thorough patient care while reducing manual data entry . it also enables us to provide a higher level of service through early identification and thorough reporting of device errors , saving customers the time and expense of unnecessary on-site visits . story_separator_special_tag research and development expenses decreased $ 3.6 million , or 38 % , for the year ended december 31 , 2018 , compared to the same period of 2017 , primarily due to lower employment costs as a result of the company-wide reduction in workforce in may 2017. general and administrative expenses increased $ 1.0 million , or 9 % , for the year ended december 31 , 2018 , compared to the same period of 2017 . this increase was primarily due to severance expense of $ 0.7 million and additional stock-based compensation expense from the modification of equity awards of $ 0.7 million related to the departure of the chief executive officer and chief financial officer and higher legal expense , partially offset by lower employment and consulting expenses as a result of the company-wide reduction in workforce in may 2017 . 41 restructuring expense of $ 0.7 million for the year ended december 31 , 2017 included employee severance payments of $ 0.4 million , stock compensation expense of $ 0.2 million related to restricted stock units issued to terminated employees , and $ 0.1 million of other related severance related benefits . there was no comparable amount during the same period in 2018 . change in fair value , contingent liabilities decreased $ 0.3 million , or 89 % , for the year ended december 31 , 2018 compared to the same period of 2017 . this was due to the decrease in the fair value of the contingent consideration liability related to equipois sales earn-outs as the obligation was no longer contingent as of december 31 , 2018 and fair value of contingent success fee related to the outstanding debt with our lender in conformance with the decrease in our stock price . other income , net gain on revaluation of warrant liabilities of $ 1.1 million for the year ended december 31 , 2018 , related to warrants issued in 2015. gain on revaluation of warrant liabilities of $ 3.9 million for the year ended december 31 , 2017 , related to warrants issued in 2015 and 2017. gains and losses on revaluation of warrants are primarily driven by changes in our stock price . loss on repurchase of warrants of $ 1.1 million for the year ended december 31 , 2017 , was associated with the difference in the fair value of the april 2017 warrants on the date of repurchase and the repurchase price . there was no comparable amount during the same period in 2018 . other ( expense ) income , net decreased $ 0.7 million , or 244 % , for the year ended december 31 , 2018 , compared to the same period of 2017 , due to unrealized gains and losses on foreign currency revaluations of monetary assets and liabilities . financial condition , liquidity and capital resources since our inception , we have devoted our efforts toward the development of exoskeletons for the medical and industrial markets , toward the commercialization of our medical exoskeletons to rehabilitation centers and toward raising capital . we have financed our operations primarily through the issuance and sale of equity securities for cash consideration and through bank debt . cash and working capital cash on hand at december 31 , 2018 was $ 7.7 million , compared to $ 27.8 million at december 31 , 2017 . since our inception , we have incurred recurring net losses and negative cash flows from operations . we have incurred net losses of $ 27.0 million and $ 29.1 million for the years ended december 31 , 2018 and 2017 , respectively . in addition , our operating activities have used $ 22.2 million and $ 31.2 million in cash for the years ended december 31 , 2018 and 2017 , respectively . liquidity and capital resources as of december 31 , 2018 , we had an accumulated deficit of $ 171.1 million and cash on hand of $ 7.7 million . largely as a result of significant research and development activities related our advanced technology and commercialization of this technology into our medical device business , we have incurred significant operating losses and negative cash flows from operations since inception . in the year ended december 31 , 2018 , we used $ 22.2 million of cash in our operations . cash on hand at december 31 , 2018 was $ 7.7 million , compared to $ 27.8 million at december 31 , 2017 . as noted in note 9 in the notes to our consolidated financial statements under the caption long-term debt , borrowings under our long-term debt agreement have a requirement of minimum cash on hand roughly equivalent to three months of cash burn . as of december 31 , 2018 , the most recent determination of this restriction , $ 5.3 million of cash must remain as unrestricted , with such amounts to be re-computed at each month end . after considering cash restrictions , effective unrestricted cash as of december 31 , 2018 is estimated to be $ 2.4 million . based on current forecasted amounts , our cash on hand will not be sufficient to satisfy our operations for the next twelve months from the date of issuance of these consolidated financial statements , which raises substantial doubt about our ability to continue as a going concern . based upon our current cash resources , the recent rate of using cash for operations and investment , and assuming modest increases in current revenue offset by incremental increases in expenses related to increased sales and marketing , we believe we have sufficient resources to meet our financial obligations until late in the second quarter of 2019. we will require significant additional financing . our actual capital requirements may vary significantly and will depend on many factors . our plans to continue our investments ( i ) in clinical and sales initiatives to accelerate adoption of the ekso robotic

net cash used in operations decreased $ 9.1 million , or 29 % , for the year ended december 31 , 2018 , compared to the same period of 2017 , primarily due to decreased employment costs as a result of the company-wide reduction in workforce in may 2017 and an increase in cash collections related to an increase in sales . net cash used in investing activities net cash used in investing activities decreased $ 0.3 , or 71 % , during the year ended december 31 , 2018 , compared to the same period of 2017 , primarily due to the absence of capitalized implementation cost associated with our new enterprise resource planning system which was implemented in october 2017. net cash provided by financing activities net cash provided by financing activities of $ 2.3 million for the year ended december 31 , 2018 was from the sale of common stock under our `` at the market offering '' program resulting in cash proceeds of $ 4.4 million , partially offset by aggregate principal payments of $ 2.2 million related to our $ 7.0 million term loan . net cash provided by financing activities of $ 42.6 million for the year ended december 31 , 2017 was driven by proceeds from the sale of common stock related to the rights offering in august 2017 and the equity financing in april 2017. off-balancesheet arrangements our liquidity is not dependent on the use of off-balance sheet financing arrangements ( as that term is defined in item 303 ( a ) ( 4 ) ( ii ) of regulation s-k ) and as of december 31 , 2018 , we had no such arrangements .


 Write a concise suspicious activity report of the following text delimited by triple backquotes. Return your response as a formal report which covers the key points highlighting the location,dates,entity names and account holder information in chronological order of the text.
     ```net cash used in operations decreased $ 9.1 million , or 29 % , for the year ended december 31 , 2018 , compared to the same period of 2017 , primarily due to decreased employment costs as a result of the company-wide reduction in workforce in may 2017 and an increase in cash collections related to an increase in sales . net cash used in investing activities net cash used in investing activities decreased $ 0.3 , or 71 % , during the year ended december 31 , 2018 , compared to the same period of 2017 , primarily due to the absence of capitalized implementation cost associated with our new enterprise resource planning system which was implemented in october 2017. net cash provided by financing activities net cash provided by financing activities of $ 2.3 million for the year ended december 31 , 2018 was from the sale of common stock under our `` at the market offering '' program resulting in cash proceeds of $ 4.4 million , partially offset by aggregate principal payments of $ 2.2 million related to our $ 7.0 million term loan . net cash provided by financing activities of $ 42.6 million for the year ended december 31 , 2017 was driven by proceeds from the sale of common stock related to the rights offering in august 2017 and the equity financing in april 2017. off-balancesheet arrangements our liquidity is not dependent on the use of off-balance sheet financing arrangements ( as that term is defined in item 303 ( a ) ( 4 ) ( ii ) of regulation s-k ) and as of december 31 , 2018 , we had no such arrangements .
```    
 Suspicious Activity Report : financial highlights in april 2017 , we sold 3,732,356 shares of our common stock and warrants to purchase 1,866,178 shares of common stock with an exercise price of $ 4.10 per share , or the april 2017 warrants for aggregate net proceeds of $ 10.9 million . in august 2017 , we sold an aggregate of 34.0 million shares of our common stock for net proceeds of $ 33.7 million . in connection with this offering , we repurchased the april 2017 warrants . in august 2018 , we announced additional purchase orders by ford motor company for the eksovest as part of an expanded initiative to help reduce the physical toll of repeated overhead tasks among ford assembly line workers , in which eksovest was supplied to 15 ford assembly plants in seven countries . in august 2018 , we entered into a controlled equity offering sm sales agreement , or the atm agreement , under which we may issue and sell shares of our common stock , having an aggregate offering price of up to $ 25.0 million . in the year ended december 31 , 2018 , we sold 2.0 million shares of our common stock under the atm agreement at an average price of $ 2.39 per share , for aggregate proceeds of $ 4.4 million , net of commission and issuance costs , to us . in december 2018 , we secured purchase orders for the eksovest from two global aerospace manufacturers to create and expand pilot programs , respectively . the assistive devices will be piloted by workers on the assembly production lines of commercial and defense airplanes to enhance safety , reduce fatigue and risk of injury . in january 2019 , we entered into the china jv to develop and serve the exoskeleton market in china and other asian markets and to create a global exoskeleton manufacturing center . in connection with the china jv , one of the joint venture partner affiliates agreed to purchase an aggregate of 3,067,485 shares of our common stock at a price per share equal to $ 1.63 , for aggregate proceeds to us of $ 5.0 million , which we received in february 2019. in addition , within thirty ( 30 ) business days of the china jv delivering its first batch of finished eksogt products to a buyer , the china jv or the joint venture partner are to invest a further $ 5.0 million in our company in accordance with the terms of the jv agreement . business we design , develop and sell exoskeleton technology that currently has applications in healthcare and industrial markets . our wearable exoskeletons are worn over clothing and are mechanically controlled by a trained operator to augment human strength , endurance and mobility . our exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities . we have sold and rented devices that ( a ) enable individuals with neurological conditions affecting gait ( e.g . , sci or stroke ) to rehabilitate and to walk again ; and ( b ) allow industrial workers to perform heavy duty or repetitive work for extended periods . in the u.s. there are about 5.9 million stroke and sci rehabilitation sessions conducted on about 680,000 stroke and sci patients at 16,900 facilities , according to lexisnexis risk solutions medical claims data . the first step to achieving our goal is for us to focus on selling and renting our medical exoskeletons to rehabilitation centers and hospitals in the united states and europe . ekso bionics began that effort with the february 2012 sale of ekso , an exoskeleton for 37 sci rehabilitation . we expanded that effort with the launch of our variableassist software . variableassist software enables users with any amount of lower extremity strength to contribute their own power for either leg to achieve self-initiated walking . next , we introduced ekso gt and smartassist which builds on the experience of ekso and variableassist , allowing us to expand our sales and marketing efforts beyond sci-focused centers to centers supporting stroke and related neurological patients . we also continue to offer rental options for ekso gt to our customers as part of our sales strategy to familiarize customers with the device and demonstrate the value-add to their business , as well as increase adoption . all rentals or sales also include customer training , comprised of both on-line and in-person training of our customers ' physical therapists , to get our customers comfortable using our product and understanding its functionality . we have continued to progress toward our goal with the roll out of our latest breakthrough innovation , smartassist . smartassist can aid in promoting early mobility by training patients ( pregait ) to walk in an exoskeleton , which should expand access to care to more patients . smartassist also includes next generation variableassist technology that provides more freedom for healthcare providers to allow patients to power themselves ( freegait ) in the most appropriate ways possible . additionally , we have strengthened our competitive position as an exoskeleton manufacturer in medical rehabilitation by introducing a cloud-based software platform named eksopulse analytics , which gathers and transmits statistics and device information in real time during ekso gt walking sessions . this feature enables more thorough patient care while reducing manual data entry . it also enables us to provide a higher level of service through early identification and thorough reporting of device errors , saving customers the time and expense of unnecessary on-site visits . story_separator_special_tag research and development expenses decreased $ 3.6 million , or 38 % , for the year ended december 31 , 2018 , compared to the same period of 2017 , primarily due to lower employment costs as a result of the company-wide reduction in workforce in may 2017. general and administrative expenses increased $ 1.0 million , or 9 % , for the year ended december 31 , 2018 , compared to the same period of 2017 . this increase was primarily due to severance expense of $ 0.7 million and additional stock-based compensation expense from the modification of equity awards of $ 0.7 million related to the departure of the chief executive officer and chief financial officer and higher legal expense , partially offset by lower employment and consulting expenses as a result of the company-wide reduction in workforce in may 2017 . 41 restructuring expense of $ 0.7 million for the year ended december 31 , 2017 included employee severance payments of $ 0.4 million , stock compensation expense of $ 0.2 million related to restricted stock units issued to terminated employees , and $ 0.1 million of other related severance related benefits . there was no comparable amount during the same period in 2018 . change in fair value , contingent liabilities decreased $ 0.3 million , or 89 % , for the year ended december 31 , 2018 compared to the same period of 2017 . this was due to the decrease in the fair value of the contingent consideration liability related to equipois sales earn-outs as the obligation was no longer contingent as of december 31 , 2018 and fair value of contingent success fee related to the outstanding debt with our lender in conformance with the decrease in our stock price . other income , net gain on revaluation of warrant liabilities of $ 1.1 million for the year ended december 31 , 2018 , related to warrants issued in 2015. gain on revaluation of warrant liabilities of $ 3.9 million for the year ended december 31 , 2017 , related to warrants issued in 2015 and 2017. gains and losses on revaluation of warrants are primarily driven by changes in our stock price . loss on repurchase of warrants of $ 1.1 million for the year ended december 31 , 2017 , was associated with the difference in the fair value of the april 2017 warrants on the date of repurchase and the repurchase price . there was no comparable amount during the same period in 2018 . other ( expense ) income , net decreased $ 0.7 million , or 244 % , for the year ended december 31 , 2018 , compared to the same period of 2017 , due to unrealized gains and losses on foreign currency revaluations of monetary assets and liabilities . financial condition , liquidity and capital resources since our inception , we have devoted our efforts toward the development of exoskeletons for the medical and industrial markets , toward the commercialization of our medical exoskeletons to rehabilitation centers and toward raising capital . we have financed our operations primarily through the issuance and sale of equity securities for cash consideration and through bank debt . cash and working capital cash on hand at december 31 , 2018 was $ 7.7 million , compared to $ 27.8 million at december 31 , 2017 . since our inception , we have incurred recurring net losses and negative cash flows from operations . we have incurred net losses of $ 27.0 million and $ 29.1 million for the years ended december 31 , 2018 and 2017 , respectively . in addition , our operating activities have used $ 22.2 million and $ 31.2 million in cash for the years ended december 31 , 2018 and 2017 , respectively . liquidity and capital resources as of december 31 , 2018 , we had an accumulated deficit of $ 171.1 million and cash on hand of $ 7.7 million . largely as a result of significant research and development activities related our advanced technology and commercialization of this technology into our medical device business , we have incurred significant operating losses and negative cash flows from operations since inception . in the year ended december 31 , 2018 , we used $ 22.2 million of cash in our operations . cash on hand at december 31 , 2018 was $ 7.7 million , compared to $ 27.8 million at december 31 , 2017 . as noted in note 9 in the notes to our consolidated financial statements under the caption long-term debt , borrowings under our long-term debt agreement have a requirement of minimum cash on hand roughly equivalent to three months of cash burn . as of december 31 , 2018 , the most recent determination of this restriction , $ 5.3 million of cash must remain as unrestricted , with such amounts to be re-computed at each month end . after considering cash restrictions , effective unrestricted cash as of december 31 , 2018 is estimated to be $ 2.4 million . based on current forecasted amounts , our cash on hand will not be sufficient to satisfy our operations for the next twelve months from the date of issuance of these consolidated financial statements , which raises substantial doubt about our ability to continue as a going concern . based upon our current cash resources , the recent rate of using cash for operations and investment , and assuming modest increases in current revenue offset by incremental increases in expenses related to increased sales and marketing , we believe we have sufficient resources to meet our financial obligations until late in the second quarter of 2019. we will require significant additional financing . our actual capital requirements may vary significantly and will depend on many factors . our plans to continue our investments ( i ) in clinical and sales initiatives to accelerate adoption of the ekso robotic

